IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Associated Banc Corp

Associated Banc Corp lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,772 shares of the medical research company's stock after purchasing an additional 3,495 shares during the period. Associated Banc Corp owned about 0.07% of IQVIA worth $26,091,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of IQV. Smith Group Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth approximately $1,616,000. Simplify Asset Management Inc. boosted its holdings in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock worth $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new position in shares of IQVIA during the 4th quarter worth approximately $941,000. Finally, Fifth Third Bancorp boosted its holdings in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts recently commented on IQV shares. Truist Financial reiterated a "buy" rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Barclays decreased their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Citigroup decreased their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Stock Down 0.9 %

NYSE:IQV traded down $1.75 during trading hours on Wednesday, hitting $186.80. The company's stock had a trading volume of 1,008,388 shares, compared to its average volume of 1,227,564. The stock has a market capitalization of $32.93 billion, a P/E ratio of 24.91, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The stock has a fifty day moving average of $196.06 and a 200-day moving average of $209.52. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.34.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.